Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

20. April 2015 06:30 ET | Quelle: Atara Biotherapeutics, Inc.

EBV-CTL Clinical Trial Data Presented by Atara Biotherapeutics' Collaborating Investigators at a Plenary Session at the American Association for Cancer Research Annual Meeting 2015

SOUTH SAN FRANCISCO, Calif., April 20, 2015 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA) today announced that its collaborating investigators at Memorial Sloan Kettering Cancer Center...
19. April 2015 08:30 ET | Quelle: Atara Biotherapeutics, Inc.

Atara Biotherapeutics' Collaborating Investigators' Abstract on T-Cell Therapy for EBV Lymphoma to be Presented at a Clinical Trials Plenary Session at the American Association for Cancer Research Annual Meeting 2015 is Now Available

SOUTH SAN FRANCISCO, Calif., April 19, 2015 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), today announced that the abstract on cytotoxic T lymphocytes activated against Epstein-Barr...
13. April 2015 06:30 ET | Quelle: Atara Biotherapeutics, Inc.

Atara Biotherapeutics, Inc. to Present at the 2015 Jefferies Immuno-Oncology Summit

SOUTH SAN FRANCISCO, Calif., April 13, 2015 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA) today announced that Isaac Ciechanover, M.D., the company's Chief Executive Officer, will...
09. April 2015 06:30 ET | Quelle: Atara Biotherapeutics, Inc.

Atara Biotherapeutics, Inc. to Present at the Needham Healthcare Conference

SOUTH SAN FRANCISCO, Calif., April 9, 2015 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA) today announced that Gad Soffer, the company's Chief Operating Officer, will present at the...
27. März 2015 06:30 ET | Quelle: Atara Biotherapeutics, Inc.

Atara Biotherapeutics, Inc. Appoints Eric Dobmeier, Chief Operating Officer of Seattle Genetics, Inc., to Its Board of Directors

SOUTH SAN FRANCISCO, Calif., March 27, 2015 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company focused on developing innovative therapies for patients with...
19. März 2015 06:30 ET | Quelle: Atara Biotherapeutics, Inc.

Atara Biotherapeutics' Collaborating Investigators to Present Clinical Data on T-Cell Therapy for EBV Lymphoma at a Clinical Trials Plenary Session at the American Association for Cancer Research Annual Meeting 2015

SOUTH SAN FRANCISCO, Calif., March 19, 2015 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), today announced that its collaborating investigators at Memorial Sloan Kettering Cancer...
03. März 2015 06:30 ET | Quelle: Atara Biotherapeutics, Inc.

Atara Biotherapeutics Names David A. Carmel as Head of Immunotherapy

SOUTH SAN FRANCISCO, Calif., THOUSAND OAKS, Calif., and NEW YORK, March 3, 2015 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company focused on innovative...
02. März 2015 06:30 ET | Quelle: Atara Biotherapeutics, Inc.

FDA Grants Breakthrough Therapy Designation to Epstein-Barr Virus (EBV) Targeted T-Cells for Treatment of EBV-Associated Lymphoproliferative Disease

SOUTH SAN FRANCISCO, Calif., March 2, 2015 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA) today announced that its collaborative partner, Memorial Sloan Kettering Cancer Center (MSK)...
26. Februar 2015 16:05 ET | Quelle: Atara Biotherapeutics, Inc.

Atara Biotherapeutics Announces Fourth Quarter and Full Year 2014 Operating Results

SOUTH SAN FRANCISCO, Calif., Feb. 26, 2015 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company with a focus on developing innovative therapies for patients...
18. Februar 2015 16:21 ET | Quelle: Atara Biotherapeutics, Inc.

Atara Biotherapeutics Announces Closing of Underwritten Offering of Common Stock and Exercise of Underwriters' Option to Purchase Additional Shares

SOUTH SAN FRANCISCO, Calif., Feb. 18, 2015 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical development company with a focus on innovative therapies for patients with...

Vorherige Seite